|
1）The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology. 1999; 53: 457-65
|
|
|
|
2）Sriram S, Steiner I. Experimental allergic encephalomyelitis: A misleading model of multiple sclerosis. Ann Neurol. 2005; 60: 12-21
|
|
|
|
|
|
3）Metz I, Lucchinetti CF, Openshaw H, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain. 2007; 130: 1254-62
|
|
|
|
|
|
4）Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47: 707-17
|
|
|
|
|
|
5）Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol. 2004; 55: 458-68
|
|
|
|
|
|
6）中原 仁，鈴木則宏．インターフェロンβによる多発性硬化症の再発予防．診断と治療．2015; 103: 1179-85
|
|
|
|
|
|
7）中原 仁. α4インテグリン: ナタリズマブ．Brain Nerve. 2014; 66; 1149-58
|
|
|
|
|
|
8）Proia RL, Hla T. Emerging biology of sphingosine-1-phosphaet: Its role in pathogenesis and therapy. J Clin Invest. 2015; 125: 1379-87
|
|
|
|
|
|
9）Menge T, Stüve O, Kieseier BC, et al. Alemtuzumab: The advantages and challenges of a novel therapy in MS. Neurology. 2014; 83: 87-97
|
|
|
|
|
|
10）Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012; 78: 1069-78
|
|
|
|
|
|
11）Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008; 359: 1786-801
|
|
|
|
|
|
12）Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain. 2010; 133: 1914-29
|
|
|
|
|
|
13）Barkhof F. MRI in multiple sclerosis: Correlation with expanded disability status scale (EDSS). Mult Scler. 1999; 5: 283-6
|
|
|
|
|
|
14）Popescu V, Agosta F, Hulst HE, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013; 84: 1082-91
|
|
|
|
|
|
15）De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010; 74: 1868-76
|
|
|
|
|
|
16）Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014; 75: 43-9
|
|
|
|
|
|
17）Haider L, Simeonidou C, Steinberger G, et al. Multiple sclerosis deep gray matter: The relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry. 2014; 85: 1386-95
|
|
|
|
|
|
18）Fischer MT, Wimmer I, Höftberger R, et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain. 2013; 136: 1799-815
|
|
|
|
|
|
19）Hametner S, Wimmer I, Haider L, et al. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol. 2013; 74: 848-61
|
|
|
|
|
|
20）Miller DH, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015; 84: 1145-52
|
|
|
|
|
|
21）Cohen JA, Khatri B, Barkhof F, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis; Results from the extension of the randomized TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2015. In press
|
|
|
|
|
|
22）Nakahara J, Kanekura K, Nawa M, et al. Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis. J Clin Invest. 2009; 119: 169-81
|
|
|
|
|